<SEC-DOCUMENT>0001477932-25-004069.txt : 20250521
<SEC-HEADER>0001477932-25-004069.hdr.sgml : 20250521
<ACCEPTANCE-DATETIME>20250521170008
ACCESSION NUMBER:		0001477932-25-004069
CONFORMED SUBMISSION TYPE:	CB
PUBLIC DOCUMENT COUNT:		13
FILED AS OF DATE:		20250521
DATE AS OF CHANGE:		20250521

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Renergen Ltd
		CENTRAL INDEX KEY:			0001953578
		STANDARD INDUSTRIAL CLASSIFICATION:	GAS & OTHER SERVICES COMBINED [4932]
		ORGANIZATION NAME:           	01 Energy & Transportation
		EIN:				000000000
		STATE OF INCORPORATION:			T3
		FISCAL YEAR END:			0228

	FILING VALUES:
		FORM TYPE:		CB
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-95047
		FILM NUMBER:		25973815

	BUSINESS ADDRESS:	
		STREET 1:		1 BOMPAS ROAD
		CITY:			DUNKELD WEST
		STATE:			T3
		ZIP:			2196
		BUSINESS PHONE:		27100456000

	MAIL ADDRESS:	
		STREET 1:		1 BOMPAS ROAD
		CITY:			DUNKELD WEST
		STATE:			T3
		ZIP:			2196

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ASP Isotopes Inc.
		CENTRAL INDEX KEY:			0001921865
		STANDARD INDUSTRIAL CLASSIFICATION:	MISCELLANEOUS CHEMICAL PRODUCTS [2890]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				872618235
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CB

	BUSINESS ADDRESS:	
		STREET 1:		601 PENNSYLVANIA AVENUE NW
		STREET 2:		SOUTH BUILDING, SUITE 900
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20004
		BUSINESS PHONE:		202-756-2245

	MAIL ADDRESS:	
		STREET 1:		601 PENNSYLVANIA AVENUE NW
		STREET 2:		SOUTH BUILDING, SUITE 900
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20004
</SEC-HEADER>
<DOCUMENT>
<TYPE>CB
<SEQUENCE>1
<FILENAME>aspi_cb.htm
<DESCRIPTION>FORM CB
<TEXT>
<html><head><title>aspi_cb.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="margin:0px"> <p style="margin:0px"> <table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>UNITED STATES </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Washington, D.C. 20549</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><font style="font-size:18pt">Form&nbsp;CB</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>TENDER OFFER/RIGHTS OFFERING NOTIFICATION FORM</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>(AMENDMENT NO. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Please place an X in the box(es) to designate the appropriate rule&nbsp;provision(s)&nbsp;relied upon to file this Form:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Securities Act Rule&nbsp;801 (Rights Offering)</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Securities Act Rule&nbsp;802 (Exchange Offer)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9746;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Exchange Act Rule&nbsp;13e-4(h)(8)&nbsp;(Issuer Tender Offer)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Exchange Act Rule&nbsp;14d-1(c)&nbsp;(Third Party Tender Offer)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Exchange Act Rule&nbsp;14e-2(d)&nbsp;(Subject Company Response)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#9744;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 5.4pt; text-align:center;"><strong><font style="font-size:18pt">Renergen Limited</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 5.4pt; text-align:center;">(Name of Subject Company)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 5.4pt; text-align:center;"><strong>Not applicable</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Translation of Subject Company&#8217;s Name into English (if applicable))</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 5.4pt; text-align:center;"><strong>Republic of South Africa</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Jurisdiction of Subject Company&#8217;s Incorporation or Organization)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px 0px 0px 5.4pt"><strong><font style="font-size:18pt">ASP Isotopes Inc.</font></strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">(Name of Person(s)&nbsp;Furnishing Form)</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 5.4pt; text-align:center;"><strong>Ordinary Shares</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Title of Class&nbsp;of Subject Securities)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 5.4pt; text-align:center;"><strong>ISIN &nbsp;ZAE000202610</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(CUSIP Number of Class&nbsp;of Securities (if applicable))</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Stefano Marani</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Chief Executive Officer</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Renergen Limited</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Sandton Gate, Second Floor,</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>25 Minerva Avenue,</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Glenadrienne, Sandton,</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Gauteng, 2196</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>South Africa</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Tel:&nbsp; +27 10 045 6000</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Name, Address (including zip code) and Telephone Number (including area code) of</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Person(s)&nbsp;Authorized to Receive Notices and Communications on Behalf of Subject Company)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">with a copy to:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Donald Ainscow, Esq.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Blank Rome LLP</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>200 Crescent Court, Suite 1000</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Dallas, TX 75201</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Tel: +1 (972) 850-1450</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>May 20, 2025 (Publication of Joint Firm Intention Announcement)</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 5.4pt; text-align:center;">Date Business Combination Commenced</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">This Notification on Form&nbsp;CB is being furnished by ASP Isotopes&nbsp;Inc., a Delaware corporation (the&nbsp;&#8220;Company&#8221;), in connection with the Company&#8217;s announcement of its firm intention (&#8220;FIA&#8221;) to acquire 100% of the ordinary shares (excluding treasury shares) of Renergen Limited (&#8220;Renergen&#8221;), a South African company listed on the exchange operated by the JSE Limited, pursuant to a scheme of arrangement under South African law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>PART&nbsp;I - INFORMATION SENT TO SECURITY HOLDERS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>Item 1.&nbsp;Home Jurisdiction Documents</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">(a) The following documents are attached as exhibits to this Form CB:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Exhibit No.</strong></p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px 0px 0px 0in"><strong>Document</strong></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">99.1*</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Combined Circular to Renergen Shareholders</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">99.2*</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Circular to Renergen Shareholders in Relation to Shareholder Ratification Resolution</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td colspan="3" style="width:95%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">* To be filed by amendment.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>Item 2. Informational Legends</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">A legend complying with Rule&nbsp;802(b)&nbsp;under the Securities Act of 1933 will be included in the Combined Circular to Renergen Shareholders and the Circular to Renergen Shareholders in Relation to Shareholder Ratification Resolution.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>PART&nbsp;II - INFORMATION NOT REQUIRED TO BE SENT TO SECURITY HOLDERS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">(1)&nbsp;&nbsp;&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Exhibit No.</strong></p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px 0px 0px 0in"><strong>Document</strong></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="aspi_ex993.htm">99.3</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="aspi_ex993.htm">Joint Firm Intention Announcement dated May 20, 2025 made by ASP Isotopes&nbsp;Inc. and Renergen was made publicly available in accordance with the requirements of Renergen&#8217;s home jurisdiction and is attached hereto as Exhibit 99.3.</a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="aspi_ex994.htm">99.4</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><a href="aspi_ex994.htm">The Press Release of ASP Isotopes Inc. dated May 20, 2025 and entitled &#8220;ASP Isotopes Inc. Announces an Agreement Relating to the Potential Acquisition of Renergen Limited Expected to Create a Global Critical Materials Company&#8221; was made publicly available in the United States and is attached hereto as Exhibit 99.4.</a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">99.5*</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Pre-listing Statement for the purposes of complying with the JSE Listings Requirements in connection with the listing of ASP Isotopes&nbsp;Inc. shares of common stock on the Main Board of the Johannesburg Stock Exchange.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="3"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="3"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">* To be filed by amendment.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">(2)&nbsp;&nbsp;&nbsp;</p></td> <td colspan="3"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Not applicable.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td> <td></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">(3)&nbsp;&nbsp;&nbsp;</p></td> <td colspan="3"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Not applicable.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>PART&nbsp;III - CONSENT TO SERVICE OF PROCESS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Not applicable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>PART&nbsp;IV &#8212; SIGNATURES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">After due inquiry and to the best of my knowledge and belief,&nbsp;I certify that the information set forth in this statement is true, complete and correct.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>ASP Isotopes&nbsp;Inc.</strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:3%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">/s/ Paul Mann</p></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Paul Mann</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Chief Executive Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Date: May 21, 2025</p></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>2
<FILENAME>aspi_ex993.htm
<DESCRIPTION>JOINT FIRM INTENTION ANNOUNCEMENT
<TEXT>
<html><head><title>aspi_ex993.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 99.3</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:42%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="aspi_ex992img10.jpg"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>RENERGEN LIMITED</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Incorporated in the Republic of South Africa)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Registration number 2014/195093/06)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">JSE and A2X Share code: REN</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">ISIN: ZAE000202610 </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">LEI:378900B1512179F35A69</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Australian Business Number (ABN): 93 998 352 675</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">ASX Share code: RLT</p></td> <td style="width:42%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="aspi_ex992img11.jpg"> </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ASP ISOTOPES INC.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Incorporated in the State of Delaware, United States of America)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Delaware file number 6228898)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Ticker Symbol: NASDAQ: ASPI</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">ISIN: US00218A1051</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(&#8220;<strong>Renergen</strong>&#8221;)</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(&#8220;<strong>ASPI</strong>&#8221;)</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>JOINT ANNOUNCEMENT OF THE FIRM INTENTION OF ASPI TO MAKE AN OFFER TO ACQUIRE ALL THE ORDINARY SHARES IN RENERGEN BY WAY OF A SCHEME OF ARRANGEMENT OR STANDBY GENERAL OFFER AND CAUTIONARY ANNOUNCEMENT</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:1%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>1. </strong></p></td> <td style="vertical-align:top;"><strong>SUMMARY</strong></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;">The boards of directors of ASPI and Renergen are pleased to announce that they have reached agreement, subject to the conditions detailed below, on the terms of the all-share offer to be made by ASPI to acquire the entire issued ordinary share capital of Renergen.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;">The combination of these companies will:</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">create a global critical materials entity capable of producing critical and strategically important materials, with strong earnings potential, enabling global megatrends such as medical, semiconductors, green energy and space exploration;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">create a vertically and horizontally integrated supply chain with an attractive cost position, enabling the group to compete in a range of geographies;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">provide geographic diversification, with customers and operations in the US, South Africa, UK, Europe and the Middle East; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">drive substantial inward investment into South Africa, create employment opportunities and strengthen the domestic supply chain.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>2.</strong></p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>INTRODUCTION</strong></p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2.1.</p></td> <td style="vertical-align:top;">Shareholders of Renergen (&#8220;<strong>Renergen Shareholders</strong>&#8221;) are advised that ASPI has submitted a letter of firm intention (as contemplated in Chapter 5 of the South African Companies Act, 2008 (&#8220;<strong>Companies Act</strong>&#8221;) and Chapter 5 of the South African Companies Regulations, 2011 (&#8220;<strong>Companies Regulations</strong>&#8221;)) (&#8220;<strong>Firm Intention Offer Letter</strong>&#8221;) to the Renergen board of directors (&#8220;<strong>Renergen Board</strong>&#8221;), in terms of which ASPI will make an offer to acquire all of Renergen&#8217;s issued ordinary no par value shares (&#8220;<strong>Renergen</strong> <strong>Shares</strong>&#8221;), in consideration for which ASPI will issue new common stock (&#8220;<strong>Consideration Shares</strong>&#8221;) to the Renergen Shareholders, as detailed in paragraphs 2.3 to 2.5 below (&#8220;<strong>Offer</strong>&#8221;), which Offer has been accepted by the Renergen Board.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2.2.</p></td> <td style="vertical-align:top;">An independent board of Renergen directors has been constituted in relation to the Offer, as required under the Companies Regulations, and is comprised of David King (Chairman), Mbali Swana and Dumisa Hlatshwayo, being the independent non-executive directors of Renergen which, after consideration of all facts including the circumstances set out in regulation 108(8) of the Companies Regulations, have been determined to be independent for purposes of the Offer (&#8220;<strong>Independent Board</strong>&#8221;).</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2.3.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">ASPI proposes to implement the Offer:</p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2.3.1.</p></td> <td style="vertical-align:top;">by way of a scheme of arrangement (&#8220;<strong>Scheme</strong>&#8221;) to be proposed by the Independent Board between Renergen and Renergen Shareholders in accordance with section 114(1)(d) of the Companies Act; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2.3.2.</p></td> <td style="vertical-align:top;">if the Scheme lapses or fails, solely due to one or more Scheme Condition (as defined below) not being fulfilled or, where applicable, not being waived, ASPI, as part of the same Offer, will automatically and without further action being required from it, make an offer to acquire up to 100% of the Renergen Shares from Renergen Shareholders by way of general standby offer, which will not be subject to any condition as to acceptances (&#8220;<strong>Standby Offer</strong>&#8221;).</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2.4.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Subject to the provisions of paragraph 6 below, in consideration for the Renergen Shares acquired by ASPI from Renergen Shareholders (whether acquired in terms of the Scheme or the Standby Offer), Renergen Shareholders will receive Consideration Shares in the ratio of 0.09196 Consideration Shares for every 1 (one) Renergen Share (&#8220;<strong>Consideration Ratio</strong>&#8221;).</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2.5.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">ASPI is seeking a secondary inward listing of the ASPI common stock on the Main Board of the JSE Limited (&#8220;<strong>JSE</strong>&#8221;) (&#8220;<strong>Secondary Listing</strong>&#8221;) and the Consideration Shares offered to holders of Renergen Shares recorded in the JSE share register will be listed on the JSE, while Consideration Shares offered to holders of Renergen CHESS Depositary Interests tradeable on the Australian Securities Exchange (&#8220;<strong>ASX</strong>&#8221;) will be listed on the NASDAQ.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2.6.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The purpose of this announcement is to advise Renergen Shareholders of the terms and conditions of the Offer and the mechanics of the Scheme and the Standby Offer, and to inform Renergen Shareholders of the status of the ASPI Funding Arrangements (described more fully in paragraph 14 below) as conditionally exempted by the Takeover Panel, upon which ASPI and the Independent Board have agreed.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>3.</strong></p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>OVERVIEW OF ASPI </strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">3.1.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">ASPI has been listed on the NASDAQ under the trading symbol &#8220;ASPI&#8221; since November 2022. ASPI has operations across various jurisdictions and operates principally through its subsidiaries in Guernsey, South Africa and the United Kingdom.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">3.2.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">ASPI is an advanced materials company dedicated to the development of technology and processes that, if successful, will allow for the enrichment of natural isotopes into higher concentration products, which could be used in several industries. ASPI&#8217;s proprietary technologies, the Aerodynamic Separation Process (&#8220;<strong>ASP technology</strong>&#8221;) and Quantum Enrichment technology (&#8220;<strong>QE technology</strong>&#8221;), are designed to enable the production of isotopes used in several industries. ASPI&#8217;s initial focus is on the production and commercialization of enriched Carbon-14 (&#8220;<strong>C-14</strong>&#8221;), Silicon-28 (&#8220;<strong>Si-28</strong>&#8221;) and Ytterbium-176 (&#8220;<strong>Yb-176</strong>&#8221;).</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">3.3.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">ASPI has completed the commissioning phase and is commencing commercial production at its C-14 and Si-28 enrichment facilities in Pretoria, South Africa. ASPI has also completed the commissioning phase and are commencing production of commercial samples of highly enriched Yb-176 at its Yb-176 enrichment facility in Pretoria, South Africa. ASPI&#8217;s C-14 and Si-28 enrichment facilities utilize the ASP technology and its Yb-176 enrichment facility utilizes QE technology. ASPI expects its first three enrichment facilities to generate commercial product during 2025. In addition, ASPI has started planning additional isotope enrichment plants both in South Africa and in other jurisdictions, including Iceland and the United States. ASPI believes the C-14 it may produce using the ASP technology could be used in the development of new pharmaceuticals and agrochemicals. ASPI believes the Si-28 it may produce using the ASP technology may be used to create advanced semiconductors and in quantum computing. ASPI believes the Yb-176 it may produce using the QE technology may be used to create radiotherapeutics that treat various forms of oncology.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">3.4.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">In addition, ASPI is considering the future development of the ASP technology for the separation of Zinc-68, Xenon-129/136 for potential use in the healthcare end market, Germanium 70/72/74 for potential use in the semiconductor end market, and Chlorine -37 for potential use in the nuclear energy end market. ASPI is also considering the future development of QE technology for the separation of Nickel-64, Gadolinium-160, Ytterbium-171, Lithium-6 and Lithium-7.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">3.5.</p></td> <td style="vertical-align:top;">ASPI is currently pursuing an initiative to apply its enrichment technologies to the enrichment of Uranium-235 (&#8220;<strong>U-235</strong>&#8221;) in South Africa. ASPI believes that the U-235 it may produce using QE technology may be commercialized as a nuclear fuel component for use in the new generation of high-assay low-enriched uranium (HALEU)-fuelled small modular reactors that are now under development for commercial and government uses. In furtherance of its uranium enrichment initiative, in October 2024, ASPI entered into a term sheet with TerraPower, LLC (&#8220;<strong>TerraPower</strong>&#8221;) which contemplates the parties entering into definitive agreements pursuant to which TerraPower would provide funding for the construction of a HALEU production facility and agree to purchase all HALEU produced at the facility over a 10-year period after the planned completion of the facility in 2027. In addition, in November 2024, ASPI entered into a memorandum of understanding with The South African Nuclear Energy Corporation (Necsa), a South African state-owned company responsible for undertaking and promoting research and development in the field of nuclear energy and radiation sciences, to collaborate on the research, development and ultimately the commercial production of advanced nuclear fuels. Subject to the receipt of funding and all required permits and licenses to begin enrichment of U-235 in South Africa, it is anticipated that the research, development and ultimate construction of a HALEU production facility will take place at South Africa&#8217;s main nuclear research centre at Pelindaba in Pretoria.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">3.6.</p></td> <td style="vertical-align:top;">ASPI operates principally through subsidiaries: ASP Isotopes Guernsey Limited (the holding company of ASP Isotopes efh (a subsidiary incorporated in Iceland), ASP Isotopes South Africa (Proprietary) Limited, Enlightened Isotopes (Pty) Ltd), ASPI South Africa Asset Finance (Pty) Ltd, and ASP Isotopes UK Limited, which will be focused on the development and commercialization of high-value, low-volume isotopes for highly specialized end markets (such as C-14, Si-28 and Yb-176). In September 2023, ASPI formed a new subsidiary, Quantum Leap Energy LLC, which also has a subsidiary in the United Kingdom (Quantum Leap Energy Ltd), to focus on the development and commercialization of advanced nuclear fuels such as HALEU and Lithium-6. ASP Isotopes UK Ltd is the owner of ASPI&#8217;s technology. In addition, ASPI has a 51% ownership stake in Pet Labs Pharmaceuticals Proprietary Limited (PET Labs), a South African radiopharmaceutical operations company focused on the production of fluorinated radioisotopes and active pharmaceutical ingredients, through which it entered the downstream medical isotope production and distribution market.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>4.</strong></p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>RATIONALE</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.1.</p></td> <td style="vertical-align:top;">In today's volatile geopolitical landscape, where critical materials security has become paramount to national interests, the strategic business combination between ASPI and Renergen creates a uniquely positioned global entity in critical and strategically important materials vital to the healthcare, semiconductor manufacturing and energy sectors.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.2.</p></td> <td style="vertical-align:top;">Isotopes have one of the most severely compromised supply chains in the world. Isotope supply is mostly controlled by Rosatom State Nuclear Energy Corporation, the Russian state-owned entity, and two small European producers. The United States Department of Energy and other governments across the world have identified isotopes as critical material. Many industries and defence capabilities that are critical to national security in the US, Europe and elsewhere face existential risk without secure isotope supply.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.3.</p></td> <td style="vertical-align:top;">The timing of the transaction is opportune. China's recent export restrictions on critical materials, including gallium, germanium and graphite have exposed significant vulnerabilities in global supply chains, with western and other governments recognizing the key importance of securing access to critical materials and other strategic resources that are increasingly necessary to maintain economic and military strength. This business combination directly addresses these concerns by creating a resilient, vertically integrated supplier of essential critical materials.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.4.</p></td> <td style="vertical-align:top;">Global demand for helium in semiconductor manufacturing alone is projected to increase total consumption significantly; therefore this business combination combines ASPI's world-leading silicon-28 enrichment capabilities with Renergen's helium reserves to address critical supply vulnerabilities. Renergen's Virginia Gas Project boasts some of the highest helium concentrations recorded globally, providing a secure supply alternative at a time when helium prices have surged over 400% amid severe supply constraints.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.5.</p></td> <td style="vertical-align:top;">This business combination offers strong growth potential. ASPI brings a proven track record of exceptional project execution and leadership &#8216;on the ground&#8217; in South Africa &#8211; having completed construction of three enrichment facilities in South Africa in the past three years. It has also developed extensive engineering and fabrication facilities in South Africa that may support accelerated project construction and cost savings. Renergen has recently completed construction of its first liquid helium and liquid natural gas (&#8220;<strong>LNG</strong>&#8221;) plant in South Africa, having developed highly advanced cryogenic engineering skills, while ASPI has transitioned from development to commercialization of high-value isotopes including silicon-28, carbon-14, and ytterbium-176, each backed by multi-year supply agreements. Producing these isotopes is highly energy intensive, with energy costs representing 90% of the cost of goods. Leveraging power from Renergen&#8217;s large-scale LNG plant could potentially reduce ASPI&#8217;s energy costs by up to 94%.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.6.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">ASPI is also a key global player in the clean energy transition, working with a number of world-leading nuclear reactor companies, such as TerraPower, to enrich uranium to produce HALEU for use in the next generation of nuclear power plants: small modular reactors. ASPI has worked extensively with the South African Government body, Necsa, on this project and will start construction of their plant at Pelindaba in 2H25.</p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.7.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Renergen&#8217;s financial position faces significant liquidity concerns due to a delayed Phase 1 of the Virginia Gas Project, as it addressed some of the technical challenges common in commissioning a highly technical and specialised liquefaction facility. The business however has several significant tailwinds and unique opportunities, which makes it an attractive asset. Should the Scheme not materialise, Renergen will most likely be required to undertake a capital raise to complete Phase 1 of the Virginia Gas Project. The proposed transaction achieves substantial benefits for shareholders in both companies as it:</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.7.1.</p></td> <td style="vertical-align:top;">addresses Renergen&#8217;s immediate liquidity needs, providing the necessary capital to complete Phase 1 and progress to Phase 2 of the Virginia Gas Project;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.7.2.</p></td> <td style="vertical-align:top;">enhances Renergen&#8217;s ability to accelerate its business plan, leveraging (i) expertise of recently appointed Kinley Exploration who are supporting reservoir engineering, well design and location for both remaining planned wells for Phase 1C and Phase 2, (ii) recent operational milestones such as the completion of the liquid helium production train and (iii) increased LNG production from the completion and ramp up of the plant from the Phase 1C project;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.7.3.</p></td> <td style="vertical-align:top;">offers existing Renergen Shareholders a premium on their investment, as the Offer is structured to deliver value above the current Renergen Share price. Based on the volume weighted average price (&#8220;<strong>VWAP</strong>&#8221;) of Renergen Shares on the JSE over the 30 trading days up to and including Friday, 16 May 2025 of ZAR 6.68; and the VWAP of ASPI Common Stock on the NASDAQ over the same period of USD 5.69, the Offer consideration amounts to a premium of c. 41.3%, when applying the Consideration Ratio and the ruling ZAR to USD exchange rate on Friday, 16 May 2025 of USD 1 : ZAR 18.04;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.7.4.</p></td> <td style="vertical-align:top;">unlocks the potential the Virginia Gas Project holds with Phase 2 and beyond, allowing both ASPI and Renergen&#8217;s shareholders to participate in the development of the Virginia Gas Project, but also allowing Renergen shareholders to participate in the development of ASPI&#8217;s business in speciality gases; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.7.5.</p></td> <td style="vertical-align:top;">creates a strategic materials company with vertical and horizontal business integration without equal in the industry, from which all shareholders will benefit.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.8.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Renergen&#8217;s proven resource base and strategic partnerships position it well for future success once combined with ASPI, as it continues to develop its unique helium and LNG assets.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.9.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The combined entity benefits from ASPI's US capital markets expertise, as well as its NASDAQ listing which has attracted US and global institutional investors who understand how fragile global critical material supply chains are. The combined benefit of Renergen becoming part of a US company, together with its existing funding committed from the United States Development Finance Corporation and, producing critical materials for the purpose of bringing them into the US and other jurisdictions, will enhance their strong government and regulatory relationships.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.10.&nbsp;</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">ASPI and Renergen have a shared, complimentary customer base with both companies serving end markets in medical (helium, carbon-14, ytterbium), nuclear (uranium, helium) and semiconductor (silicon-28, helium, germanium) industries, enabling immediate operational and sales synergies. Renergen have already built an extensive sales network within the semiconductor sector which may significantly increase sales targets for ASPI.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.11.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The combined entity's diverse portfolio of high-margin industrial materials provides natural revenue diversification in one of the highest growth markets globally with &#8220;Big Tech&#8221; expected to spend over USD 300 billion in AI infrastructure capex in 2025 alone. By combining ASPI&#8217;s proprietary isotope enrichment technologies, ASPI and QE, with Renergen&#8217;s Virginia Gas Project, ASPI-Renergen is expected to be well-positioned in the global industrial materials market.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>5.</strong></p></td> <td colspan="4" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>MECHANICS AND TERMS OF THE OFFER</strong></p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:7%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.1.</p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>The Scheme:</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.1.1.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The Scheme will constitute an affected transaction as defined in section 117(1)(c) of the Companies Act and will be regulated in terms of the Companies Act, the Companies Regulations and by the Takeover Regulations Panel (&#8220;<strong>Takeover Panel</strong>&#8221;) and by the JSE Limited (&#8220;<strong>JSE</strong>&#8221;).</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.1.2.</p></td> <td colspan="2" style="vertical-align:top;">The Scheme will be implemented in terms of section 114 of the Companies Act and will be proposed by the Independent Board between Renergen and the Renergen Shareholders, including Renergen CHESS Depositary Interests tradeable on the ASX.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.1.3.</p></td> <td colspan="2" style="vertical-align:top;">A combined circular to Renergen Shareholders in relation to the Offer, as contemplated in regulations 106(2) and 106(3) of the Companies Regulations (&#8220;<strong>Circular</strong>&#8221;) will be prepared, the distribution of which will be subject to the conditions precedent set out in paragraph 8 below (&#8220;<strong>Posting Conditions</strong>&#8221;).</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.1.4.</p></td> <td colspan="2" style="vertical-align:top;">The Scheme will be subject to the conditions precedent set out in paragraph 9.1 below (&#8220;<strong>Offer Conditions</strong>&#8221;) and the conditions precedent set out in paragraph 9.2 below (&#8220;<strong>Scheme Conditions</strong>&#8221;), and if such conditions are not fulfilled or, where permissible, waived by the longstop date set out in paragraph 9 below, the Scheme will fail and will not become operative.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.1.5.</p></td> <td colspan="2" style="vertical-align:top;">Should the Scheme become operative:</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.1.5.1.</p></td> <td style="vertical-align:top;">Renergen Shareholders will receive the Consideration Shares in accordance with the Consideration Ratio, as detailed in paragraph 6 below;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.1.5.2.</p></td> <td style="vertical-align:top;">ASPI will become the registered and beneficial owner of all the Renergen Shares and as a consequence thereof and Renergen will become a wholly owned subsidiary of ASPI; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.1.5.3.</p></td> <td style="vertical-align:top;">application will be made to the JSE, A2X and ASX for the termination of the listing or quotation of Renergen Shares on the JSE, A2X and ASX.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.1.6.</p></td> <td colspan="2" style="vertical-align:top;">Should the Scheme become operative:</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Renergen is expected to be removed from the official list of the ASX on or about the end of August 2025. Renergen Shareholders are advised that if they wish to sell their Renergen Shares on the ASX, they will need to do so before then.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.2.</p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Standby Offer</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.2.1.</p></td> <td colspan="2" style="vertical-align:top;">In the event that:</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.2.1.1.</p></td> <td style="vertical-align:top;">the Circular has been distributed;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.2.1.2.</p></td> <td style="vertical-align:top;">the Offer Conditions have been fulfilled and, where applicable, waived; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.2.1.3.</p></td> <td style="vertical-align:top;">the Scheme lapses or fails solely due to one or more of the Scheme Conditions not being fulfilled or waived, as permissible (&#8220;<strong>Standby Offer Trigger Event</strong>&#8221;),</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">the Stand-by Offer will automatically become effective and open for acceptance by the Renergen Shareholders immediately once ASPI and Renergen have announced through SENS and on the ASX<strong> </strong>that the Standby Offer Trigger Event has occurred and that the Scheme has therefore failed.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.2.2.</p></td> <td colspan="2" style="vertical-align:top;">The consideration payable for each Renergen Share in respect of which the Standby Offer is accepted will be equal to the consideration offered by ASPI in terms of the Scheme as set out in paragraph 6 below.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>6.</strong></p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>OFFER CONSIDERATION</strong></p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">6.1.</p></td> <td colspan="2" style="vertical-align:top;">In consideration for the Renergen Shares acquired by ASPI from Renergen Shareholders (whether acquired in terms of the Scheme or the Stand-by Offer), Renergen Shareholders will receive the Consideration Shares in the Consideration Ratio of 0.09196 Consideration Shares for every 1 (one) Renergen Share, provided that:</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">6.1.1.</p></td> <td style="vertical-align:top;">the number of Consideration Shares will be rounded down to the nearest whole number resulting in allocations of whole Consideration Shares only;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">6.1.2.</p></td> <td style="vertical-align:top;">in respect of any fractional entitlements that arise, ASPI will make cash payments to the applicable Renergen Shareholders in accordance with the JSE Listings Requirements (&#8220;<strong>Fractional Cash Payments</strong>&#8221;); and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">6.1.3.</p></td> <td style="vertical-align:top;">the Consideration Ratio has been calculated on the basis that there will be 155,170,891 Renergen Shares capable of participating in the Scheme or the Standby Offer, which includes (i) the Renergen Shares in issue on the date of this announcement and (ii) the Renergen Shares which Renergen is obliged to issue in terms of the Renergen Bonus Share Plan, approved in 2017 (&#8220;<strong>Bonus Share Plan</strong>&#8221;). Subject to rounding down to the nearest whole number, a maximum of 14,270,000 Consideration Shares will be issued by ASPI as consideration in terms of the Scheme or the Standby Offer, therefore should there be more than 155,170,891 Renergen Shares in issue or required to be issued, the Consideration Ratio will be adjusted downwards on a <em>pro rata</em> basis to reflect same.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">6.2.</p></td> <td colspan="2" style="vertical-align:top;">If any Renergen Shares are required to be issued to AIRSOL SRL in terms of Renergen&#8217;s convertible debentures or for any other reason, the Consideration Ratio will be adjusted downward on a <em>pro rata</em> basis to reflect same as the maximum Consideration Shares shall at all times be capped at 14,270,000 Consideration Shares.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">6.3.</p></td> <td colspan="2" style="vertical-align:top;">ASPI confirms that it has sufficient authorised common stock available from which to issue the Consideration Shares to Renergen Shareholders in terms of the Offer.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">6.4.</p></td> <td colspan="2" style="vertical-align:top;"><strong>Cash Confirmation</strong></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">6.4.1.</p></td> <td style="vertical-align:top;">The Fractional Cash Payments to Renergen Shareholders in accordance with paragraph 6.1.2, will be funded by ASPI.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">6.4.2.</p></td> <td style="vertical-align:top;">In accordance with regulations 111(4) and 111(5) of the Companies Regulations, ASPI has provided an irrevocable cash confirmation to the Takeover Panel which confirms that, ASPI has sufficient cash resources in terms of regulation 111(4)(a) of the Companies Regulations, to satisfy payment to Renergen Shareholders of the maximum Fractional Cash Payments.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>7.</strong></p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>CONDUCT OF BUSINESS UNDERTAKINGS</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">In terms of the Firm Intention Offer Letter, ASPI and Renergen have both given certain undertakings to carry on their respective businesses in all material respects in the ordinary course, consistent with past practice, and in accordance with their policies and strategies in order to maintain the respective business values and protect shareholder value (&#8220;<strong>Conduct of Business Undertakings</strong>&#8221;) during the period between the date of signature of the Firm Intention Offer Letter and the earlier of: (i) the implementation of the Scheme or the Stand-by Offer; and (ii) the date on which it is announced on SENS and the ASX that the Offer has failed. The Conduct of Business Undertakings will be detailed in the Circular.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>8.</strong></p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>CIRCULAR POSTING CONDITIONS</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">8.1.</p></td> <td colspan="2" style="vertical-align:top;">The posting of the Circular to Renergen Shareholders will be subject to the fulfilment of the following Posting Conditions that, by no later than 30 June 2025:</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">8.1.1.</p></td> <td style="vertical-align:top;">the Independent Expert (as defined below) has delivered its opinion in respect of the Offer consideration to the Independent Board, in accordance with section 114 of the Companies Act and regulations 90 and 110 of the Companies Regulations;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">8.1.2.</p></td> <td style="vertical-align:top;">the Independent Expert has delivered to Renergen an opinion that the terms and conditions, including the consideration offered to Renergen Shareholders under the Offer, are reasonable to Renergen Shareholders;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">8.1.3.</p></td> <td colspan="2" style="vertical-align:top;">following receipt of the above opinion from the Independent Expert, the Independent Board has recommended that Renergen Shareholders vote in favour of the Scheme, or alternatively, accept the Standby Offer; and</td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:7%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">8.1.4.</p></td> <td colspan="2" style="vertical-align:top;">all requisite approvals have been received from the JSE, ASX, the Takeover Panel and the Financial Surveillance Department of the South African Reserve Bank (&#8220;<strong>FinSurv</strong>&#8221;) for the posting of the Circular, to the extent required.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">8.2.</p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The Posting Conditions cannot be waived.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">8.3.</p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Subject to regulatory requirements, ASPI will be entitled to extend the date for the fulfilment of the Posting Conditions by up to 45 (forty-five) days, in its sole discretion, upon written notice to Renergen. Any extension longer than the aforementioned period, must be agreed in writing by ASPI and Renergen.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>9.</strong></p></td> <td colspan="4" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>OFFER AND SCHEME CONDITIONS</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.1.</p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Offer Conditions</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The Offer (including the Scheme and the Standby Offer) will be subject to the fulfilment or, where permissible, waiver of the following Offer Conditions (which, for the avoidance of doubt are in addition to the Posting Conditions set out in paragraph 8.1 above) that, by no later than 30 September 2025 (&#8220;<strong>Longstop Date</strong>&#8221;):</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.1.1.</p></td> <td colspan="2" style="vertical-align:top;">the written consent for the transfer of the Renergen Shares in terms of the Offer is obtained from the Industrial Development Corporation of South Africa and the United States International Development Finance Corporation (&#8220;<strong>Lenders</strong>&#8221;) in terms of the change of control provisions under their respective loan and/or funding arrangements with Renergen and subsidiaries of Renergen and that the Lenders agree not to proceed in foreclosing on outstanding debt due by those subsidiaries, as a result of any breach of covenants, event of default or otherwise, prior to 31 July 2027;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.1.2.</p></td> <td colspan="2" style="vertical-align:top;">the written consent for the transfer of the Renergen Shares in terms of the Offer is obtained from The Standard Bank of South Africa (&#8220;<strong>SBSA</strong>&#8221;) in terms of the change of control provisions under its respective loan(s) and/or funding arrangement(s) with Renergen and SBSA agrees to extend the repayment date for the loan(s) and/or funding arrangement(s) to at least 31 March 2026;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.1.3.</p></td> <td colspan="2" style="vertical-align:top;">AIRSOL SRL agrees to extend the maturity date for the convertible debentures that it holds in Renergen, to at least 31 March 2026;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.1.4.</p></td> <td colspan="2" style="vertical-align:top;">that all regulatory approvals, except for the requirement that Takeover Panel issue a compliance certificate to Renergen in terms of section 121(b) of the Companies Act, required to implement the Offer are obtained, including:</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.1.4.1.</p></td> <td style="vertical-align:top;">the FinSurv granting such approvals with respect to the Offer, as are required in terms of the Exchange Control Regulations, 1961 (&#8220;<strong>Exchange Control Regulations</strong>&#8221;) to implement the Offer either unconditionally, or subject to conditions acceptable to ASPI in its sole discretion;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.1.4.2.</p></td> <td style="vertical-align:top;">the JSE granting all requisite approvals in terms of the JSE Listings Requirements with respect to the Offer; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.1.4.3.</p></td> <td style="vertical-align:top;">the ASX and Australian Securities &amp; Investments Commission granting such approvals (if any) as are required with respect to the Offer (to the extent required);</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.1.5.</p></td> <td colspan="2" style="vertical-align:top;">that all regulatory approvals required for the Secondary Listing of ASPI Common Stock are obtained, including:</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.1.5.1.</p></td> <td style="vertical-align:top;">the FinSurv granting such approvals with respect to the Secondary Listing, as are required in terms of the Exchange Control Regulations, to implement the Secondary Listing;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.1.5.2.</p></td> <td style="vertical-align:top;">the JSE granting all requisite approvals in terms of the JSE Listings Requirements with respect to the Secondary Listing;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.1.6.</p></td> <td colspan="2" style="vertical-align:top;">the relevant competition authorities granting such approvals as are required in terms of the Competition Act, 1998 and other applicable laws to implement the Offer, either unconditionally or subject to conditions acceptable to ASPI in its sole discretion;</td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:7%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.1.7.</p></td> <td colspan="2" style="vertical-align:top;">a general meeting of Renergen Shareholders is held to consider the Shareholder Ratification resolution (as defined in paragraph 14.6.2 below) and such resolution has been adopted by ordinary resolution; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.1.8.</p></td> <td colspan="2" style="vertical-align:top;">a Material Adverse Change (as defined below) has not occurred by the date on which the last of the conditions to the Scheme or the Standby Offer, other than this condition, has been fulfilled or waived;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">For purposes of this paragraph 9.1.8, the term &#8220;<strong>Material Adverse Change</strong>&#8221; shall mean:</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.1.8.1.</p></td> <td style="vertical-align:top;">Renergen having committed a breach of any of its material Conduct of Business Undertakings, which will be detailed in the Circular and, where such breach is capable of being remedied, not having remedied such breach within 30 (thirty) business days of receipt of written notice from ASPI requiring it to do so; and/or</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.1.8.2.</p></td> <td style="vertical-align:top;">any event, change or circumstance (or any series of combination thereof) that has occurred, or may reasonably be expected to occur which, individually or in aggregate, will have, or is reasonably likely to have a material adverse effect on the business, operations, financial condition or prospects of Renergen and/or a subsidiary of Renergen. For the purposes of this clause &#8220;materially adverse effect&#8221; shall mean anything that is expected to result in a reduction of at least 20% (twenty percent) in the Renergen group&#8217;s enterprise/equity value, comprising the total equity value (as per the Consolidated Statement of Financial Position in Renergen&#8217;s most recently published annual results (&#8220;<strong>SOFP</strong>&#8221;)) plus interest bearing borrowings (as per the SOFP), excluding the impact of any funding provided by ASPI to Renergen, as determined by an auditor or independent expert appointed by the parties on agreement within 3 days of receipt of notification from Renergen or if there is no agreement then by the most senior officer for the time being of the South African Institute of Chartered Accountants. Renergen shall promptly notify ASPI in writing upon becoming aware of any actual or potential Material Adverse Change. A reduction in enterprise/equity value will not constitute a material adverse effect to the extent it results from (i) any event, change or circumstance which is temporary in nature; (ii) changes in accounting standards; or (iii) any fact fairly disclosed in writing to ASPI prior to the date of the Offer.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;">In order to comply with section 121(b) of the Companies Act and regulation 102(13) of the Companies Regulations, notwithstanding the fulfilment of the conditions, the Offer shall not be implemented unless and until the Takeover Panel has issued a compliance certificate in respect of the Offer in terms of section 119(4)(b) of the Companies Act.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.2.</p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Scheme Conditions</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">In addition to the Offer Conditions, the Scheme will be subject to (and will only become operative on the relevant operational date upon) the fulfilment or, where permissible, waiver of the following Scheme Conditions that, by no later than the Longstop Date:</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.2.1.</p></td> <td colspan="2" style="vertical-align:top;">either:</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.2.1.1.</p></td> <td style="vertical-align:top;">no Renergen Shareholder (i) gives notice objecting to the resolution required to approve the Scheme in terms of section 115(2) of the Companies Act (&#8220;<strong>Scheme Resolution</strong>&#8221;), as contemplated in section 164(3) of the Companies Act, and (ii) votes against the Scheme Resolution at the general meeting to be convened by Renergen to approve the Scheme Resolution (&#8220;<strong>Scheme Meeting</strong>&#8221;); or</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.2.1.2.</p></td> <td style="vertical-align:top;">if any Renergen Shareholder gives notice objecting to the Scheme Resolution as contemplated in section 164(3) of the Companies Act and then votes against the Scheme Resolution at the Scheme Meeting, that no Renergen Shareholders exercise their appraisal rights, by giving valid demands in terms of sections 164(5) to 164(8) of the Companies Act;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.2.2.</p></td> <td colspan="2" style="vertical-align:top;">the Scheme Resolution is approved by the requisite majority of votes of the Renergen Shareholders at the Scheme Meeting as contemplated in section 115(2) of the Companies Act;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.2.3.</p></td> <td colspan="2" style="vertical-align:top;">to the extent required in terms of section 115(3)(a) of the Companies Act, the High Court of South Africa approves the implementation of the Scheme Resolution;</td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:7%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.2.4.</p></td> <td colspan="2" style="vertical-align:top;">if any person who voted against the Scheme Resolution applies to court for a review of the Scheme Resolution in terms of section 115(3)(b) and section 115(6) of the Companies Act, either:</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.2.4.1.</p></td> <td style="vertical-align:top;">leave to apply to court for any such review is refused; or</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.2.4.2.</p></td> <td style="vertical-align:top;">if leave is so granted, the court refuses to set aside the Scheme Resolution; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.2.5.</p></td> <td colspan="2" style="vertical-align:top;">the Scheme Resolution is not withdrawn or treated as a nullity.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.3.</p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Waiver and Extension</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.3.1.</p></td> <td colspan="2" style="vertical-align:top;">ASPI may, by notice in writing to Renergen, waive:</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.3.1.1.</p></td> <td style="vertical-align:top;">the Offer Conditions in paragraphs 9.1.1, 9.1.2, 9.1.3 and/or 9.1.8; and/or</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.3.1.2.</p></td> <td style="vertical-align:top;">the Scheme Condition in paragraph 9.2.1.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9.3.2.</p></td> <td colspan="2" style="vertical-align:top;">Subject to regulatory requirements, ASPI will be entitled to extend the Longstop Date for the fulfilment of the Offer Conditions and the Scheme Conditions by up to 60 (sixty) days, in its sole discretion, upon written notice to Renergen. Any extension longer than the aforementioned period, must be agreed in writing by ASPI and Renergen.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>10.</strong></p></td> <td colspan="4" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>SHAREHOLDING IN RENERGEN AND ACTING AS PRINCIPAL</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">10.1.</p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">ASPI confirms that it is the ultimate prospective purchaser of the Renergen Shares and is acting alone and not in concert with any party.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">10.2.</p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The ASPI group does not hold any Renergen Shares and does not hold any option to purchase any beneficial interest in Renergen.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>11.</strong></p></td> <td colspan="4" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>REPORT OF THE INDEPENDENT EXPERT</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">11.1.</p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The Independent Board has appointed Forvis Mazars Corporate Finance Proprietary Limited as the independent expert (&#8220;<strong>Independent Expert</strong>&#8221;), as required in terms of section 114(2) of the Companies Act and the Companies Regulations, to issue a report dealing with the matters set out in sections 114(2) and 114(3) of the Companies Act and regulations 90 and 110 of the Companies Regulations, and express an opinion on whether the terms and conditions of the Offer (including the Consideration Ratio) are fair and reasonable to Renergen Shareholders.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">11.2.</p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The report of the Independent Expert in this regard will be provided in the Circular.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>12.</strong></p></td> <td colspan="4" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>IRREVOCABLE UNDERTAKINGS</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="4" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The Renergen Shareholders listed below, collectively holding 35,86% of the aggregate issued Renergen Shares including the Renergen Shares which Renergen is obliged to issue in terms of the Bonus Share Plan, provided irrevocable undertakings to vote in favour of the resolutions to be proposed at the Scheme Meeting and accept the Standby Offer, in respect of the Renergen Shares held by them at the time of the Scheme Meeting. </p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;border-right:#000000 1px solid;border-bottom:#000000 1px solid;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%" cellpadding="2"> <tr style="height:15px"> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Renergen Shareholder </strong></p></td> <td class="hdcell" style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;width:33%;vertical-align:bottom;text-align:center;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Number of Renergen Shares</strong></p></td> <td class="hdcell" style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;width:33%;vertical-align:bottom;text-align:center;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>% of Renergen&#8217;s issued share capital <sup style="vertical-align:super">1</sup></strong></p></td></tr> <tr style="height:15px"> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Mazi Asset Management (Pty) Ltd on behalf of its clients</p></td> <td class="ffcell" style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;text-align:right;">20,944,555</td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">13,50%</p></td></tr> <tr style="height:15px"> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">MATC Investments Limited (Stefano Marani)</p></td> <td class="ffcell" style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;text-align:right;">8,714,306</td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">5,62%</p></td></tr> <tr style="height:15px"> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">CRT Investments (Pty) Ltd (Nick Mitchell)</p></td> <td class="ffcell" style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;text-align:right;">8,600,269</td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">5,54%</p></td></tr> <tr style="height:15px"> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Mr Ye Jia</p></td> <td class="ffcell" style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;text-align:right;">7,972,500</td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">5,14%</p></td></tr> <tr style="height:15px"> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Anchor Capital (Pty) Ltd on behalf of its clients</p></td> <td class="ffcell" style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;text-align:right;">5,536,060</td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3,57%</p></td></tr> <tr style="height:15px"> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Ivy Asset Management on behalf of its clients</p></td> <td class="ffcell" style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;text-align:right;">3,874,893</td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2,50%</p></td></tr> <tr style="height:15px"> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Total</strong></p></td> <td class="ffcell" style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;text-align:right;"><strong>55,642,583</strong></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>35,86%</strong></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Note 1: </strong>Calculated on the basis that Renergen will have 155,170,891 shares in issue on the date of the Scheme Meeting or held by Renergen Shareholders able to accept the Standby Offer.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>13.</strong></p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>EQUITABLE TREATMENT OF SARS HOLDERS</strong></p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Renergen intends to ensure the equitable treatment of holders of share appreciation rights under the existing Renergen Equity-Settled Share Appreciation Rights Plan 2021, as required in terms of the Companies Regulations. A further announcement in this regard will be made in due course.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>14.</strong></p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>ASPI FUNDING</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">14.1.</p></td> <td colspan="2" style="vertical-align:top;">On 31 March 2025, prior to receipt of the Firm Intention Offer Letter, Renergen and ASPI entered into an exclusivity agreement (&#8220;<strong>Exclusivity Agreement</strong>&#8221;). Pursuant to this agreement, Renergen received an exclusivity payment of the ZAR equivalent amount of USD 10,000,000, which amount (&#8220;<strong>Initial Funding Amount</strong>&#8221;) has since been converted into and credited as an advance under the USD 30,000,000 bridge loan agreement subsequently concluded between Renergen and ASPI (&#8220;<strong>Loan Agreement</strong>&#8221;) (collectively, &#8220;<strong>ASPI Funding Arrangements</strong>&#8221;). In terms of the ASPI Funding Arrangements, the Initial Funding Amount will be followed by two tranches of loan amounts from ASPI of the ZAR equivalent amount of USD 10,000,000 each, to be advanced on or before 31 May 2025 and 30 June 2025, such that the total advanced amounts will be the ZAR equivalent of USD 30,000,000, to enable Renergen to meet key lender payment deadlines and avoid a default by Renergen under its existing loan/funding arrangements.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">14.2.</p></td> <td colspan="2" style="vertical-align:top;">Under the original terms of the Exclusivity Agreement, the Initial Funding Amount was repayable by Renergen if the Circular was not posted, a further loan agreement was not concluded or the Scheme was not implemented as a result of the actions or non-actions of Renergen. In order to facilitate such repayment, Renergen would implement a rights offer (&#8220;<strong>Rights Offer</strong>&#8221;), which would be underwritten by ASPI, thereby ensuring that the Rights Offer would be fully subscribed and that Renergen would receive sufficient funds to settle its repayment obligations.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">14.3.</p></td> <td colspan="2" style="vertical-align:top;">In Renergen&#8217;s engagements with the Takeover Panel, the Takeover Panel raised concerns in terms of section 126(1)(a) of the Companies Act relating to the ASPI Funding Arrangements, which concerns may be summarised as follows:</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">14.3.1.</p></td> <td style="vertical-align:top;">the structure of the ASPI Funding Arrangements may have the effect of denying Renergen Shareholders the opportunity to consider the Offer on its merits; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">14.3.2.</p></td> <td style="vertical-align:top;">the structure of the ASPI Funding Arrangements may have coercive features in that a failure to adopt the resolutions necessary to give effect to the Offer would automatically result in a rights offer underwritten by ASPI.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">14.4.</p></td> <td colspan="2" style="vertical-align:top;">While neither Renergen, nor ASPI agrees with the Takeover Panel&#8217;s characterisation of the ASPI Funding Arrangements as frustrating actions or as coercive in nature, given the financial pressures on Renergen and the need to ensure that the ASPI Funding Arrangements will be advanced to ensure that Renergen meets key lender payment deadlines, thereby avoiding a default and subsequent cross-defaults on lending agreements, Renergen and ASPI have decided to act in the most expedient way and to accommodate the Takeover Panel&#8217;s requirements and recommendations. Renergen and ASPI are clear that the reason for the ASPI Funding Arrangements is to support Renergen's operations as a going concern and are not designed to be coercive. The TRP is, however, precluded from basing its regulatory decisions on the commercial advantages or disadvantages of intended actions.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">14.5.</p></td> <td colspan="2" style="vertical-align:top;">Renergen applied for a formal exemption from the Takeover Panel in terms of section 119(6) of the Companies Act and made certain undertakings to the Takeover Panel as set out in paragraph 14.6 below.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">14.6.</p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The Takeover Panel has granted a conditional exemption in terms of section 119(6) of the Companies Act, exempting Renergen from the strict application of the prior approval requirements of section 126(1) of the Companies Act in respect of the ASPI Funding Arrangements (&#8220;<strong>Conditional Exemption</strong>&#8221;), subject to the following conditions:</p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:7%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><u>Condition 1: Definitive Implementation of Remedial Amendments to the ASPI Funding Arrangements</u></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">14.6.1.</p></td> <td colspan="2" style="vertical-align:top;">The original terms of ASPI Funding Arrangements must be legally and definitively amended to:</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">14.6.1.1.</p></td> <td style="vertical-align:top;">remove all references to a rights offer from the ASPI Funding Arrangements;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">14.6.1.2.</p></td> <td style="vertical-align:top;">remove all references to underwriting a rights offer from the ASPI Funding Arrangements; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">14.6.1.3.</p></td> <td style="vertical-align:top;">remove any relationship between the success or failure of the Offer and the repayment terms for the amounts advanced in terms of the ASPI Funding Arrangements and amend the repayment terms such that the total amounts advanced are repayable by no later than 30 September 2025, or such later date that the parties agree,</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;">(collectively, the &#8220;<strong>Remedial Amendments</strong>&#8221;).</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">14.6.2.</p></td> <td colspan="2" style="vertical-align:top;">Renergen and ASPI confirm that the terms of the ASPI Funding Arrangements have been amended to incorporate all the Remedial Amendments prior to the date of this announcement, and accordingly this condition has therefore been complied with.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><u>Condition 2: Retrospective Renergen Shareholder Approval of the Amended ASPI Funding Arrangements </u></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">14.6.3.</p></td> <td colspan="2" style="vertical-align:top;">The amended ASPI Funding Arrangements reflecting the Remedial Amendments (and the Conditional Exemption in relation thereto) must be made expressly conditional upon Renergen Shareholders ratifying and approving the actions taken by Renergen, on a retrospective basis, when it entered into the Exclusivity Agreement, which has converted into the Loan Agreement, to the extent that such actions constituted frustrating actions under section 126 of the Companies Act (&#8220;<strong>Shareholder Ratification</strong>&#8221;).</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">14.6.4.</p></td> <td colspan="2" style="vertical-align:top;">The Shareholders<strong> </strong>Ratification must be by way of an ordinary resolution at a duly constituted general meeting of Renergen Shareholders, convened by a notice and circular providing full and fair disclosure of the terms of the amended ASPI Funding Arrangements, which general meeting must be held on a date at least 10 calendar days prior to the Scheme Meeting.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">14.6.5.</p></td> <td colspan="2" style="vertical-align:top;">In this regard, Renergen confirms that a separate circular &#8211; including full and fair disclosure of the history of the ASPI Funding Arrangements, the terms of the amended ASPI Funding Arrangements (including the repayment date of 30 September 2025 or as agreed), the Panel's initial concerns as outlined in its 15 May Ruling and 16 May Guidance Letter, and this conditional exemption granted by the Panel on 17 May 2025 &#8211; (&#8220;<strong>EGM Circular</strong>&#8221;) will be distributed to Renergen Shareholders to convene an extraordinary general meeting for this purpose (&#8220;<strong>EGM</strong>&#8221;). The Offer is subject to the convening of the EGM and the adoption of the Shareholder Ratification resolution by ordinary resolution, as set out in the Offer Condition in paragraph 9.1.7 above.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><u>Condition 3: Full and Frank Disclosure in Offer Documentation </u></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">14.6.6.</p></td> <td colspan="2" style="vertical-align:top;">The Circular must, <em>inter alia</em>, clearly and accurately disclose the details of the ASPI Funding Arrangements, the Remedial Amendments and the terms of the Conditional Exemption granted by the Takeover Panel.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">14.6.7.</p></td> <td colspan="2" style="vertical-align:top;">If Renergen Shareholders do not approve the Shareholder Ratification resolution, the Conditional Exemption granted to Renergen would lapse and the ASPI Funding Arrangements, including any payments made to Renergen before or after the date of this announcement in terms of the ASPI Funding Arrangements (whether in terms of the original or amended terms) would be regarded by the Takeover Panel as not having been regularised.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>15.</strong></p></td> <td colspan="4" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>INDEPENDENT BOARD RESPONSIBILITY STATEMENT </strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="4" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The Independent Board accepts responsibility for the information contained in this announcement which relates to Renergen and confirms that, to the best of its knowledge and belief, such information which relates to Renergen is true and this announcement does not omit anything likely to affect the importance of such information.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>16.</strong></p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>ASPI BOARD RESPONSIBILITY STATEMENT </strong></p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The board of directors of ASPI accepts responsibility for the information contained in this announcement which relates to ASPI and confirms that, to the best of its knowledge and belief, such information which relates to ASPI is true and this announcement does not omit anything likely to affect the importance of such information.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>17.</strong></p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>FURTHER DOCUMENTATION AND SALIENT DATES</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">17.1.</p></td> <td colspan="2" style="vertical-align:top;">Further details of the Offer will be included in the Circular that will be distributed once all the relevant regulatory approvals have been obtained, which Circular is currently anticipated to be distributed by the end of May 2025. Likewise, the EGM Circular will be distributed before that date.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">17.2.</p></td> <td colspan="2" style="vertical-align:top;">The salient dates and times relating to the Offer will be included in the further announcement to be released by Renergen and ASPI, relating to the distribution of the Circular and the notice of the Scheme Meeting. Similarly, the salient dates and times relating to the EGM will be included in the further announcement to be released by Renergen, relating to the distribution of the EGM Circular and the notice of the EGM.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">17.3.</p></td> <td colspan="2" style="vertical-align:top;">The Circular will, <em>inter alia</em>, contain:</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">17.3.1.</p></td> <td style="vertical-align:top;">the full terms and conditions of the Offer;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">17.3.2.</p></td> <td style="vertical-align:top;">the salient dates and times in relation to the Scheme;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">17.3.3.</p></td> <td style="vertical-align:top;">the applicable <em>pro forma</em> financial effects of the Offer and the independent reporting accountants&#8217; assurance report thereon;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">17.3.4.</p></td> <td style="vertical-align:top;">the Independent Expert&#8217;s report in respect of the Offer;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">17.3.5.</p></td> <td style="vertical-align:top;">a notice convening the Scheme Meeting to consider and if deemed fit to approve, <em>inter alia</em>, the Scheme Resolution and matters ancillary thereto; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">17.3.6.</p></td> <td style="vertical-align:top;">a summary of the appraisal rights afforded to Renergen Shareholders in terms of the Companies Regulations.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>18.</strong></p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>CAUTIONARY ANNOUNCEMENT</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Given that the applicable <em>pro forma </em>financial effects of the Offer are still to be published, Renergen Shareholders are advised to exercise caution when dealing in Renergen&#8217;s securities until such publication.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Johannesburg</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">20&nbsp;May&nbsp;2025</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:33%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Transaction and Designated Advisor to Renergen</strong></p></td> <td style="width:34%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Independent Reporting Accountant</strong></p></td> <td style="width:33%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;<strong>Corporate Advisor and Sponsor to ASPI</strong></p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="aspi_ex992img12.jpg">&nbsp;&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="aspi_ex992img13.jpg"> </p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="aspi_ex992img14.jpg">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Legal Advisor to Renergen</strong></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Independent Expert</strong></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;<strong>South African Legal Advisor to ASPI</strong></p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><img src="aspi_ex992img15.jpg"> </strong></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="aspi_ex992img16.jpg"> </p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="aspi_ex992img17.jpg">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;<strong>US Legal Advisor to ASPI</strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>South African Legal Advisor to ASPI</strong></p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="aspi_ex992img18.jpg">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>AVAdvisory Pty Ltd</strong></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>DISCLAIMERS AND FOREIGN SHAREHOLDERS </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>THIS ANNOUNCEMENT IS NOT AN OFFER. IT IS AN ANNOUNCEMENT OF THE FIRM INTENTION TO MAKE AN OFFER. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER, INVITATION OR RECOMMENDATION TO ANY PERSON IN ANY JURISDICTION TO SELL OR ISSUE, OR THE SOLICITATION OF ANY VOTE OR APPROVAL OR AN OFFER TO BUY OR SUBSCRIBE FOR, ANY SECURITY, NOR SHALL THERE BE ANY SALE, ISSUANCE, TRANSFER OR DELIVERY OF THE SECURITIES REFERRED TO IN THIS ANNOUNCEMENT IN ANY JURISDICTION IN CONTRAVENTION OF APPLICABLE LAW, OR WHERE FURTHER ACTION IS REQUIRED FOR SUCH PURPOSE. IF THIS ANNOUNCEMENT IS RECEIVED IN ANY JURISDICTION IN WHICH IT IS ILLEGAL OR OTHERWISE UNLAWFUL FOR THE OFFER TO BE MADE OR ACCEPTED, THIS ANNOUNCEMENT SHOULD BE TREATED AS BEING RECEIVED FOR INFORMATION PURPOSES ONLY.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Important Notice to Renergen Shareholders in the United States</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Offer or business combination is made for the securities of a non-U.S. company (Renergen, a South African company), by means of the Scheme or the Standby Offer.&nbsp; The Offer is subject to disclosure and procedural requirements in South Africa and other non-U.S. jurisdictions that are different from those of the United States.&nbsp; The financial information relating to Renergen contained in the Circular has been/will be prepared in accordance with IFRS Accounting Standards that may not be comparable to the financial statements and financial information of US companies.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">It may be difficult for U.S. holders of Renergen ordinary shares to enforce their rights and any claims they may have arising under the federal securities laws of the United States, since Renergen is incorporated in a non-U.S. jurisdiction, and some or all of its officers and directors may be residents of a non-U.S. jurisdiction.&nbsp; U.S. holders may not be able to sue a non-U.S. company or its officers or directors in a non-U.S. court for violations of the U.S. securities laws.&nbsp; Further, it may be difficult to compel a non-U.S. company and its affiliates to subject themselves to a U.S. court's judgment. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">You should be aware that ASPI may purchase securities otherwise than under the Scheme, or Standby Offer such as in open market or privately negotiated purchases, subject to any restrictions or requirements under South African Law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This document is not subject to the requirements of Section 14(a) of the U.S. Securities Exchange Act of 1934, as amended.&nbsp; The Consideration Shares to be issued pursuant to the Scheme or the Standby Offer to Renergen Shareholders in the United States have not been registered in terms of the U.S. Securities Act 1933, as amended (&#8220;Securities Act&#8221;) and will be issued in reliance on the exemption from the registration requirements thereof provided by Rule 802 of the Securities Act.&nbsp; Such Consideration Shares will be freely tradable in the United States under applicable U.S. federal securities laws except for (i)&nbsp;any Consideration Shares acquired by affiliates of Renergen or ASPI and (ii) Consideration Shares that are issued with respect to Renergen Shares that are deemed &#8220;restricted securities&#8221; under Rule 144 of the Securities Act, which in each case may be resold in the US only in accordance with Rule 144 of the Securities Act or another applicable exemption from registration, or outside the US in accordance with Regulation S under that Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Restricted securities are securities received in non-public offerings.&nbsp; In general, Rule 144 defines restricted securities to mean securities acquired pursuant to one of the following transactions:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(i)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Securities acquired directly or indirectly from the issuer, or from an affiliate of the issuer, in a transaction or chain of transactions not involving any public offering, or pursuant to certain exemptions from registration.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(ii)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Securities acquired from the issuer that are subject to the resale limitations under Regulation D (a limited offering exemption) under the Securities Act.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(iii)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Securities acquired in a transaction or chain of transactions exempt under Rule 144A under the Securities Act, where exempts specified resales of restricted securities to qualified institutional buyers.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Renergen Shareholders who are citizens or residents of the United States should consult their own legal and tax advisers with respect to the legal and tax consequences of the Offer, including the status of their Renergen Shares as restricted securities.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Forward-Looking Statements</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This announcement contains &#8220;forward-looking statements&#8221; within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words like &#8220;may,&#8221; &#8220;will,&#8221; &#8220;likely,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;future,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;goal,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; and variations of such words and similar expressions.&nbsp; These forward-looking statements are not guarantees of future performance and involve risks, assumptions, and uncertainties, including, but not limited to, risks related to: (i) the implementation of the Scheme in the anticipated timeframe or at all; (ii) the satisfaction of the Scheme Conditions including, but not limited to, the approval of the Scheme Resolution; (iii) the failure to obtain necessary regulatory and shareholder approvals; (iv) the ability to realize the anticipated benefits of the proposed acquisition of Renergen; (v) the ability to successfully integrate the businesses; (vi) disruption from the proposed acquisition of Renergen making it more difficult to maintain business and operational relationships; (vii) the negative effects of this announcement or the consummation of the proposed acquisition of Renergen on the market price of Renergen&#8217;s or ASPI&#8217;s securities; (viii) significant transaction costs and unknown liabilities; (ix) litigation or regulatory actions related to the proposed acquisition of Renergen; and (x) such other factors as are set forth in the periodic reports filed by ASPI with the U.S. Securities and Exchange Commission (the &#8220;<strong>SEC</strong>&#8221;), including but not limited to those described under the heading &#8220;Risk Factors&#8221; in its annual reports on Form 10-K, quarterly reports on Form 10-Q and any other filings made with the SEC from time to time, which are available via the SEC&#8217;s website at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by these forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The forward-looking statements included in this announcement are made only as of the date of this announcement, and except as otherwise required by applicable securities law, neither Renergen nor ASPI assume any obligation nor do they intend to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>3
<FILENAME>aspi_ex994.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html><head><title>aspi_ex994.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 99.4</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><img src="aspi_ex994img1.jpg">&nbsp;</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong></strong>&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ASP Isotopes Inc. Announces an Agreement Relating to the Potential Acquisition of Renergen Limited Expected to Create a Global Critical Materials Company</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>- Combining these two highly complementary businesses aims to create a global leader in the production of critical and strategically important materials, including electronic gases such as helium, various fluorinated products and isotopically enriched gases.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>- Combination is expected to create a vertically and horizontally integrated supply chain with significant geographic and customer overlap. Substantial synergies expected from 2026.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>- Transaction is expected to be highly accretive to 2026 anticipated EPS.&nbsp;&nbsp;Goal of the combined group is to generate &gt;$300 million in EBITDA in 2030.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>- Highly unique Helium asset is expected to benefit from $750 million of committed debt funding from the U.S. government's development finance institution and other lenders to expand plant production capacity in South Africa.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>- Transaction has received irrevocable support from over 35% of Renergen shareholders and is expected to close during the third quarter of 2025 ahead of the planned QLE spin out. </em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>- The Company has entered into a term sheet with institutional debt investors for a potential debt financing of $30 million aggregate principal amount. </em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><strong><em>- Webinar with Paul Mann, CEO of ASP Isotopes, and Stefano Marani, CEO of Renergen to be held at 8:00am ET on Tuesday, May 20, 2025&#8211; to run through the transaction details and rationale.&nbsp;&nbsp;The webcast can be accessed here: </em></strong><strong><em><u>https://us06web.zoom.us/webinar/register/WN_AsxKWwYmTN6zi4rd_e-9ow</u></em></strong><strong><em></em></strong> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Washington, D.C., May 20, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes&#8221; or the &#8220;Company&#8221;), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that it has entered into an agreement relating to the potential acquisition of Renergen, a South African public company producing Helium and LNG (the &#8220;Combination&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">ASP&nbsp;Isotopes, following the acquisition of Renergen (the &#8220;combined group&#8221;), will benefit in a number of key aspects from a shared focus on critical and strategically important materials.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Renergen is expected to become a global leader in liquid helium production, one of the most sought-after critical minerals globally.&nbsp; Renergen&#8217;s key asset is the Virginia Gas project, where Helium concentrations are more than 10x the global average. &nbsp;This project has benefited from $40 million of US government funding pursuant to a finance agreement with the U.S. International Development Finance Corporation (U.S. DFC) and is expected to further benefit from an additional $500 million of senior debt funding from U.S. DFC and a $250 million debt facility from Standard Bank SA to expand plant production capacity in South Africa. &nbsp;The U.S. DFC partners with the private sector to advance U.S. foreign policy and strengthen national security by mobilizing private capital around the world.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">ASP Isotopes is transitioning from a development stage to a commercial stage isotope enrichment company, having already announced in 2025 that three of its enrichment plants are now commercially producing Carbon-14, Silicon-28 and Ytterbium-176. &nbsp;Isotopes have one of the most severely compromised supply chains of any material in the world and the US Department of Energy and the majority of Western governments also identify isotopes as critical materials. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Combination is expected to create a vertically and horizontally integrated supply chain potentially lowering isotope enrichment costs by 96% versus current cash costs. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The transaction is expected to be highly accretive to ASPI&#8217;s revenue, EBITDA, earnings per share and cash flow per share during 2026.&nbsp; The goal of the combined group is to generate over $300 million in EBITDA in 2030, which is expected to be driven by a mix of isotopes, helium and LNG sales into the South African energy market, based on management&#8217;s current estimates, expectations and assumptions regarding the execution on ASP Isotopes&#8217;s and Renergen&#8217;s businesses strategies.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">There will be significant end-market synergies. Liquid helium is an &#8220;irreplaceable&#8221; mineral in the medical, semiconductor and energy industries, which are also ASP Isotopes&#8217; three target markets.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">There is expected to be significant end customer overlap with the combined group servicing the semiconductor industry, medical industry, energy and space exploration. ASP Isotopes should also benefit from Renergen&#8217;s existing customer network in industrial gases significantly increasing sales targets.&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">It is anticipated that there will be additional substantial synergies, as much of the corporate infrastructure that ASP Isotopes expected to create during 2026 already exists at Renergen.&nbsp; The combined group&#8217;s headquarters will relocate to Austin, Texas, with close proximity to many of the combined group&#8217;s customers.&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The combined group will help the U.S. secure supplies of critical and strategically important materials vital in many end markets which enable tomorrow&#8217;s megatrends, such as quantum computing and advanced semiconductors.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Renergen&#8217; financial position had been facing liquidity concerns due to a delayed Phase 1 of the Virginia Gas Project, as it addressed some of the technical challenges common in commissioning a highly technical and specialized liquefaction facility. The business however has several significant tailwinds and unique opportunities, which make it an attractive asset. &nbsp;ASP Isotopes brings a proven track record of exceptional project management and leadership &#8216;on the ground&#8217; in South Africa &#8211; having completed construction of three enrichment facilities in three years. It also has extensive engineering and fabrication facilities allowing acceleration of project construction and cost savings.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The deal represents an approximate 90% discount to the latest published Virginia Gas Project NPV.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Transaction Overview</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Combination is expected to be implemented by ASP&nbsp;Isotopes acquiring Renergen pursuant to a South African scheme of arrangement, under which Renergen shareholders will receive 0.09196 new ASP&nbsp;Isotopes shares for each Renergen share held on the record date (the &#8220;Scheme&#8221;).&nbsp; If the Scheme is not implemented, solely due to one or more of the Scheme conditions not being fulfilled or waived, then ASP&nbsp;Isotopes will make a general offer to Renergen shareholders to acquire 100% of the issued share capital of Renergen (the &#8220;Standby Offer&#8221;). &nbsp;The total share consideration will not exceed 14,270,000 shares of ASP&nbsp;Isotopes common stock.&nbsp; The Combination is expected to result in Renergen shareholders owning approximately 16% of the combined group.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Should the Scheme become operative, Renergen will become an operating subsidiary of ASP&nbsp;Isotopes and continue to be led by the current management team with significant operational and project management support from ASPI&#8217;s management, engineering and R&amp;D teams. &nbsp;On completion, ASP&nbsp;Isotopes will have a listing on the Nasdaq Stock Exchange, as well as an inward secondary listing on the Main Board of the Johannesburg Stock Exchange.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Renergen and ASP&nbsp;Isotopes have obtained irrevocable undertakings from Mazi Asset Management (Pty) Ltd and other Renergen shareholders, and from the directors of Renergen who hold Renergen shares, to vote in favour of the resolutions required to approve and implement the Combination. &nbsp;These irrevocable undertakings are in excess of 35% of Renergen&#8217;s outstanding shares. &nbsp;These irrevocable undertakings remain binding if a competing proposal is made to Renergen, but cease to be binding from the date on which the Combination lapses or is withdrawn in accordance with its terms.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>The Combination will be subject to the full terms and conditions that will be set out in the shareholder circular to be published by Renergen in due course. Implementation of the Scheme is subject to Renergen shareholder approval and relevant regulatory approvals in various jurisdictions.&nbsp; It is currently expected that, subject to the satisfaction or waiver of the conditions, the Renergen shareholder meeting will be held in June 2025 and the Combination will be completed during the third quarter of 2025.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">ASP Isotopes and Renergen have previously entered into an exclusivity agreement whereby ASP Isotopes received the rights to negotiate the terms of the acquisition during an exclusive negotiation period ending on May 31, 2025. &nbsp;In April 2025, the Company paid a refundable exclusivity fee of $10 million to Renergen. &nbsp;As contemplated by the exclusivity agreement, the parties intend to negotiate a loan agreement which is expected to be put in place during May to ensure Renergen has the financial resources to continue operations and avoid default on its current debt obligations. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">None of Renergen&#8217;s existing debt or future debt is expected to have any recourse to ASP Isotopes and is secured on Renergen&#8217;s assets.&nbsp; ASP Isotopes has entered into a term sheet with institutional debt investors relating to a potential investment of an aggregate of $30 million of debt. Should this debt financing be completed, the proposed Combination should have a minimal impact on ASP Isotopes&#8217;s current cash position.&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Stefano Marani, CEO of Renergen, will become ASP Isotopes&#8217; CEO of Electronics and Space, based in Austin, Texas and he will join the board of directors of ASP Isotopes.&nbsp; Paul Mann will remain Executive Chairman and CEO of ASP Isotopes.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Commenting on the proposed Combination, Paul Mann, Chairman and CEO of ASP Isotopes, and Chairman and CEO of QLE, said:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#8220;<em>This is an exciting step for ASP Isotopes.&nbsp; With the planned Spin-Out of QLE, we have been considering the expansion of the ASP Isotopes business and this opportunity is the perfect fit for us.</em>&nbsp; <em>Both isotopes and helium are viewed by almost every western government as critically and strategically important materials. The combination of these two companies will create a company with huge strategic value and a vital part of a fragile supply chain enabling so many industries.</em>&#8221;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Commenting on the proposed Combination, Stefano Marani, CEO of Renergen, said:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#8220;<em>After a tumultuous year and half, I am excited about the combined prospects of our new company and its future. Closer alignment with the US has for the longest time been the final critical ingredient required to unlock the Virginia Gas Project and the longer-term expansion of this unique natural resource. In joining our two companies not only do we get this, but even more exciting is the expansion of the business horizontally across our key helium customer bases of nuclear, healthcare, semiconductors and rocketry. As the world becomes more insular, critical materials are quickly becoming the most sought-after commodities, and our acquisition places ASP Isotopes front and center. &nbsp;Offering customers a fully integrated supply chain reduces a significant amount of risk for them, and makes our offering incredibly valuable</em>.&#8221;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Webinar</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company will host a webinar with Paul Mann, CEO of ASP Isotopes, and Stefano Marani, CEO of Renergen at 8am ET on Tuesday May 20<sup style="vertical-align:super">th</sup>. The webcast can be accessed here: <u></u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><u></u>&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><u>https://us06web.zoom.us/webinar/register/WN_AsxKWwYmTN6zi4rd_e-9ow</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>About ASP Isotopes Inc.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (&#8220;ASP technology&#8221;). The Company&#8217;s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing. The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">There is a growing demand for isotopes such as Silicon-28 for enabling quantum computing; Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare applications, as well as Chlorine-37, Lithium-6, Lithium-7 and Uranium-235 for green energy applications. The ASP Technology (Aerodynamic Separation Process) is ideal for enriching low and heavy atomic mass molecules. For more information, please visit&nbsp;<u>www.aspisotopes.com</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Information for U.S. Persons holding Renergen Ordinary Shares</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The offer or business combination is made for the securities of a non-U.S. company (Renergen, a South African company), by means of the Scheme or the Standby Offer.&nbsp; The offer is subject to disclosure and procedural requirements in South Africa and other non-U.S. jurisdictions that are different from those of the United States.&nbsp; The financial information relating to Renergen contained in the shareholder circular to be sent to Renergen shareholders has been/will be prepared in accordance with IFRS Accounting Standards that may not be comparable to the financial statements and financial information of US companies.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">It may be difficult for U.S. holders of Renergen ordinary shares to enforce their rights and any claims they may have arising under the federal securities laws of the United States, since Renergen is incorporated in a non-U.S. jurisdiction, and some or all of its officers and directors may be residents of a non-U.S. jurisdiction.&nbsp; U.S. holders may not be able to sue a non-U.S. company or its officers or directors in a non-U.S. court for violations of the U.S. securities laws.&nbsp; Further, it may be difficult to compel a non-U.S. company and its affiliates to subject themselves to a U.S. court's judgment. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">You should be aware that ASP Isotopes may purchase securities otherwise than under the Scheme or Standby Offer, such as in open market or privately negotiated purchases, subject to any restrictions or requirements under South African law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">This document is not subject to the requirements of Section 14(a) of the U.S. Securities Exchange Act of 1934, as amended.&nbsp; The shares of ASP Isotopes common stock to be issued pursuant to the Scheme or the Standby Offer (&#8220;Consideration Shares&#8221;) to Renergen Shareholders in the United States have not been registered in terms of the U.S. Securities Act 1933, as amended (&#8220;Securities Act&#8221;) and will be issued in reliance on the exemption from the registration requirements thereof provided by Rule 802 of the Securities Act.&nbsp; Such Consideration Shares will be freely tradable in the United States under applicable U.S. federal securities laws except for (i) any Consideration Shares acquired by affiliates of Renergen or ASPI and (ii) Consideration Shares that are issued with respect to Renergen Shares that are deemed &#8220;restricted securities&#8221; under Rule 144 of the Securities Act, which in each case may be resold in the US only in accordance with Rule 144 of the Securities Act or another applicable exemption from registration, or outside the US in accordance with Regulation S under that Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Restricted securities are securities received in non-public offerings.&nbsp; In general, Rule 144 defines restricted securities to mean securities acquired pursuant to one of the following transactions:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">(i) Securities acquired directly or indirectly from the issuer, or from an affiliate of the issuer, in a transaction or chain of transactions not involving any public offering, or pursuant to certain exemptions from registration.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">(ii) Securities acquired from the issuer that are subject to the resale limitations under Regulation D (a limited offering exemption) under the Securities Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">(iii) Securities acquired in a transaction or chain of transactions exempt under Rule 144A under the Securities Act, where exempts specified resales of restricted securities to qualified institutional buyers.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Renergen Shareholders who are citizens or residents of the United States should consult their own legal and tax advisers with respect to the legal and tax consequences of the Offer, including the status of their Renergen Shares as restricted securities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Forward Looking Statements</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements can be identified by words such as &#8220;goal&#8221;, &#8220;target&#8221;, &#8220;believes,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;aims&#8221;, &#8220;intends&#8221;, &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;seeks&#8221;, &#8220;sees&#8221;, &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;positioned,&#8221; &#8220;strategy,&#8221; and words of a similar nature. Examples of forward-looking statements include, among others but are not limited to, statements relating to the completion of the transactions in the anticipated timeframe or at all, the subsequent integration of ASP Isotopes&#8217;s and Renergen&#8217;s businesses and the ability to recognize the anticipated synergies and benefits of the transactions, the access to available financing (including financing in connection with the transactions) on a timely basis and on reasonable terms, the plans for a secondary listing on the JSE, the plans for a spin-out of Quantum Leap Energy as a standalone public company, the anticipated market demand for future products of ASP Isotopes and Renergen, the future of the company&#8217;s enrichment technologies as applied to uranium enrichment, the outcome of the company&#8217;s initiative to commence enrichment of uranium in South Africa and the company&#8217;s discussions with nuclear regulators, and statements we make regarding expected operating results, such as future revenues and prospects from the potential commercialization of isotopes, future performance under contracts, and our strategies for product development, engaging with potential customers, market position, and financial results. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results, financial condition, and events may differ materially from those indicated in the forward-looking statements based upon a number of factors. Forward-looking statements are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. Therefore, you should not rely on any of these forward-looking statements. There are many important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements, including, but not limited to, risks related to: (i) the implementation of the Scheme in the anticipated timeframe or at all; (ii) the satisfaction of the Scheme conditions; (iii) the failure to obtain necessary regulatory and shareholder approvals; (iv) the ability to realize the anticipated benefits of the proposed acquisition of Renergen; (v) the ability to successfully integrate the businesses; (vi) disruption from the proposed acquisition of Renergen making it more difficult to maintain business and operational relationships; (vii) the negative effects of this announcement or the consummation of the proposed acquisition of Renergen on the market price of Renergen&#8217;s or ASPI&#8217;s securities; (viii) significant transaction costs and unknown liabilities; (ix) litigation or regulatory actions related to the proposed acquisition of Renergen; and (x) and the factors disclosed in Part I, Item 1A. &#8220;Risk Factors&#8221; of the company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and any amendments thereto and in the company&#8217;s subsequent reports and filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise. No information in this press release should be interpreted as an indication of future success, revenues, results of operation, or stock price. All forward-looking statements herein are qualified by reference to the cautionary statements set forth herein and should not be relied upon.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Use of Projections</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The financial outlook and projections, estimates and targets in this press release are forward-looking statements that are based on assumptions that are inherently subject to significant uncertainty and contingencies, many of which are beyond ASP&nbsp;Isotopes&#8217;s or Renergen&#8217;s control. Such calculation cannot be predicted with reasonable certainty and without unreasonable effort because of the timing, magnitude and variables associated with the completion of the proposed transaction with Renergen. Additionally, any such calculation, at this time, would imply a degree of precision that could be confusing or misleading to investors. Neither ASP&nbsp;Isotopes nor Renergen&#8217;s independent auditors have audited, reviewed, compiled or performed any procedures with respect to the financial projections for purposes of inclusion in this press release, and, accordingly, they did not express an opinion or provide any other form of assurance with respect thereto for the purposes of this press release. While all financial projections, estimates and targets are necessarily speculative, ASP&nbsp;Isotopes believes that the preparation of prospective financial information involves increasingly higher levels of uncertainty the further out the projection, estimate or target extends from the date of preparation. The assumptions and estimates underlying the projected, expected or target results for ASP&nbsp;Isotopes, Renergen and the combined company are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the financial projections, estimates and targets. The inclusion of financial projections, estimates and targets in this press release should not be regarded as an indication that ASP&nbsp;Isotopes, or its representatives, considered or consider the financial projections, estimates or targets to be a reliable prediction of future events. Further, inclusion of the prospective financial information in this press release should not be regarded as a representation by any person that the results contained in the prospective financial information will be achieved.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Contacts</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Jason Assad&#8211; Investor relations</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Email:&nbsp;<u>Jassad@aspisotopes.com</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Telephone: 561-709-3043</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">8</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>aspi_ex994img1.jpg
<TEXT>
begin 644 aspi_ex994img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  U *0# 2(  A$! Q$!_\0
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C*+*U!_U(HHH D6"%/NQJ/PJ2BB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>aspi_ex992img18.jpg
<TEXT>
begin 644 aspi_ex992img18.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  Y &D# 2(  A$! Q$!_\0
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M[)2MG9Q6X(52(T"Y"C ''H.!2?V?9M+-(]G SS,K2L8P3(5^Z6XY([>E:5%
M%&XM;>ZA,5S!'/$V"4D4,IP<C@^_-.M[>&VC\JWA2*/<6VHH49)R3QZDDU<H
MH RVTS3YK*2SDLX'MI26>(Q@HY)R21T.3S3=/T32='C:/2]-M[-&.6$$83=]
M<#FM7FCF@=Y6M<S/[+T_[/%!]C@\F%Q)''Y8VHP.0P'8YYS39]-L+I9UNK."
M83J$E$D8;S%'(#9Z@9-:M% ^9]S$M_#'AVUN$N;;0["&:-MR2);HK*?4$#BM
GCRU]*?10*[[BT444""BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>aspi_ex992img17.jpg
<TEXT>
begin 644 aspi_ex992img17.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  I $8# 2(  A$! Q$!_\0
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/.!^5%;-%5SR[A[&'8__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>aspi_ex992img16.jpg
<TEXT>
begin 644 aspi_ex992img16.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  P & # 2(  A$! Q$!_\0
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MCYI+6-C9K-- -O$;L\8+ >N&;GW/K6)X+UBS\(?&3XU:U-I_VFTTVWN9FLU
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M)1_PE'_")Z?_ &QYGG?:?)&?,_OXZ;L\YQG/-+ZQ3YI2:;O:VVGE8KE9X5\
M]H_9R^(JKQ@W?!Z@?9!C-;G[.O@_P>?@S#XJU;3+1K^1KGS=0N%!>"-=R?*Y
MY0!,],=37LNC_#_P;H&F:KIFCZ'!96>K;A>PQ%ML^05.>>."1QBK_AWPOH/A
M/0H]!T'38[#38BS+ A+*"QRWWB3R2:FIB>;FY;KF:?W(2A:USY!;4KCX3^&I
M-8\ ^-M"\8>"+R\!?1]0B4S!O]I#\V1M'S#'0';7V/H.I?VUX;TS6/):W^WV
ML5SY3<E-Z!MI^F:Y(_!?X5OK7]M-X&TLWN_S,^7\A;.<^7G9U]J]"4*JA5&
0. !45:T:L5IKU?<J,6C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>aspi_ex992img15.jpg
<TEXT>
begin 644 aspi_ex992img15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  ? '<# 2(  A$! Q$!_\0
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,.!Z?D56G<7O=C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>aspi_ex992img14.jpg
<TEXT>
begin 644 aspi_ex992img14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  < &$# 2(  A$! Q$!_\0
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MY..AIMKI>E+XBU?S--M!&D<!YA7 X;/:MFZAAGM@MQ"DT<GWHY%#*?P-4_\
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/JCT '2M&DQH****0S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>aspi_ex992img13.jpg
<TEXT>
begin 644 aspi_ex992img13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  : #X# 2(  A$! Q$!_\0
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.D9R?Q.YG6C%+W58__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>aspi_ex992img12.jpg
<TEXT>
begin 644 aspi_ex992img12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  _ %<# 2(  A$! Q$!_\0
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HS72T4K 9.EZ/:Z2LJ6C3;)':0K)(6 9F+,1GIDDUK444P"BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>aspi_ex992img11.jpg
<TEXT>
begin 644 aspi_ex992img11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  ] .T# 2(  A$! Q$!_\0
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M0.,<<HX##\JU*GFM>Q?)S6;Z'A7@^?4/@_>ZEX:\16-Y-X;DG:YL=6MX&F1
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,]34E%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>aspi_ex992img10.jpg
<TEXT>
begin 644 aspi_ex992img10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  I 0D# 2(  A$! Q$!_\0
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M)X'WLU.Y9UE%?*7_  V?HO\ T(=__P"!L?\ \32-^VAHJJ6_X0._X_Z?8_\
MXFK]G+L1SQ[GU=169I=XNJ:+8ZDJF-;N".<*3DJ&4-C/XUY;\7/CE8_"36=+
MTV\\.W.J_;X'G#PSK'L"L%Q@CGK4I-Z(IM)79[+17.>$_%.C^-/"]EXCT&[%
MU87:[E;HR'NC#LP/!%4OB)XRA^'_ ,/M2\77%A)J$5AY9-O&X1GW2*G4\#&[
M/X46UL%]+G88HKSOX5?$:W^*7@Q_$UKI<NF1+=26ODRR"0DJ%.[( _O?I7HE
M($[E&^A:XTZXACQODC95STR17.Z'X;:U\[^T(X)BQ7;_ !8QUZBNCFEBMX'F
MGD6.)%+.[G"J!R22>@JG:ZII>L6\ZZ5J=I>E5VL;>99 A(.,[2<5Q5<+3K5(
MU)J[C]QM&K*$7&/4\\^.7AGP/K7PVU;4O%\-M#+I]G*]G?.0LL$NW*A#U.Y@
MHV_Q=*\;_8SNM2,GC"R.XZ<HMIL'[JS'>#CW*J,_[HKQKXI_!WQM\,[>QO/$
M5U!J5A>.R1W5K+))'%)U"-O ()&2/7!]*^O/V=5\#K\([)O!@<.\F=2\\@SB
M[P-X?';&-N.-N/>O2:Y8::G$GS3VL>SU^?&M77AFQ_; U>Z\8K;MH,>M3&\%
MS$98RFP@;D .1NQV-?H1VK\\O$&BZ+XE_:VUG0_$%T;32KS69DN)EE6(HH0G
M.YN!R!UI4^HZNR/H33?$'[+.L:O::3I>F^&[B^O9DMX(AHS#>['"C)BP,D]Z
M]GT/PIX9\+Q3IX9T&QTA+A@TRV<"Q"0@8!.T<XKP[0_@;\#?#_B#3=>L?&4G
MVS3KF.ZA$NL0%"Z,&&1M&1D5[_I^L:3JD;MI>IVE^(R YMIED"D],[2<4GY%
MP-3UK\L6\/ZOXD\9^(+/1;-KRYMY+N\:%/OM''(2Q4=R!S@<G'%?J<?NU\&_
MLZ?\G3W?^[J'_H553=KLFHKM(]:_9U^.B^*K.#P+XLO,Z];IBRO)&_X_XP/N
ML?\ GJH_[Z SU!KR77_^3\(?^QBM/_08ZZ3]H?X*W/AG4G^)W@6*2WM5E%Q?
M6]KE6LY<Y^T1XZ+GDX^Z>>A./*/!/B+4/%G[2GA7Q%JS1F_O-8M&G,:[5=EV
MINQV)VY/N:I).\D1*35HR/TE[U\:?MGY_P"$A\'[>OV2ZQ_WW'7V9Z5\9_MH
M''B'P>1U^R77_H<=9T_B1K/X6=)X=\7?LLP^%M(AU:V\.'44LX5N2^CNS>:$
M&_)\KDYSS7L_A'PG\,9+;3/&'@[PMHT(FC\ZSOK:Q6)]C*1D':&&02/QKPO0
M/@%\"M0\-:5?:AXNN(;NYM(IIHQK$"[79 6&"N1R3Q7T!X/F\'Z'X?TKPGX?
M\16=Y%8P+;V\?VV.69E4=]IY.!V%.3[$P\SM*^$/VC(XYOVHK&&6-9(Y(]/1
MT89#*9""#[8K[OKX(_:<MI+[]HU+*%@DMQ:6<*,W #,S*"?Q-.G\14]CZ\D^
M%/PO:)Q)X!\/A"#N/V"(8'UQQ7QQI-OI/AS]L73K#X>7'F:7%K,<$7DR%U$;
M*!/&&YW*N9!GGA?;-7_$G[,_Q2T#PUJ&L'6K'5DM(C*]I9W$[2R(/O;590"0
M,G&><<<UJ_LCQ^"9/&]ZVI*W_"61Q%M-\UAY1A(Q)Y8_YZ#O_LDX_BJTK)N]
MS%N\DK6/M_M7P]^TGKVL>./CEIOPSTR3_1[.2"VAAS\CW4X!+M_NJZCV^;UK
M[AKX8_:*TK5O /[0^G?$.SM]]O>26]];N?N&>#:'C)[$A5/T;VK*'Q'1+8^C
M?!/P/^'/@O1H;1?#]GK%[L N+_4+99I)F[D!@0@]%7MZ]:\>U^/]DO5O&%GK
M4FKV]@UI*WVFPM+2>.VNR.@=!'@8/]W&>AR*]\\%_%/P;X]T*'4M$UJV65E!
MFLYY52>!NZLA.>/4<'L:^0?C=X*^#_@NS^R^$_$%[JGB>XN-\D/VN.>&WC))
M8N548/8#.?:JC=NS,I64;Q/MCPEXD\.^*_#-OJWA6\CO-)):&)XXFC4;#M*A
M6 ( QCI7'_M#_P#)O'B[_KWC_P#1R5A?LL?\F_Z=_P!?EU_Z--;G[0W_ ";M
MXO\ ^O>/_P!'1U-K2L:7O"Y\T? ?7O@GI/@_5(?B=!I,FIO?%[<WNGM<-Y/E
MH."$; W!N*^A/!NC?L_^/H[U_"7A?P[JB63(MPRZ4(]A8';]]!G.T]*^<?@?
M\+_AGXZ\)ZCJ/C;Q!+IM[!>F"&--0BM]T?EHV=K@D\D\^U?2GPU\+_"OX6KJ
M<7AOQ?;R)J#1O-]LU2&3!0,!C&,?>-7/=V,8;*YZO;P0V]O';P1K'#$H1$48
M"J!@ #TQ7QQ^V8<>,_"A/:PG_P#1BU]E1R)-&LD;!T8!E93D$'N#7QI^V=_R
M-_A;_L'S_P#HQ:SI_$:3^$XGX9>/O$GP)\=+IGB.UF.@ZC'%<75J/F!CD4%+
MF'L3@\XZ@%3R!C[G:/P_XV\+1M)'9ZYH>HQI*HD42PSID,IP>#R ?8BO-O$'
MPE\._%;X2^%;75'>QU"TT^V:VOX%!DB!B7<A!^\I]#WP:Z+P;X;MOA3\-8/"
M^GZD=3-D[NKS@(S>9(6(V@\8W5GB*].G!U)NUBJ5.3?*M;G5Z+X?T/PWIYT_
MP_I-II5H7,A@M(5B3<<9; &,G K<W5C:#J4NJ:<;B9%1A(5PO3BM?<M11J1K
M052&S'.+A)Q[&-XFTAO$/A'6=!6;R#J-E-:>:R[@GF(5W8[XSTKSGX(?!N?X
M16FN03:]'JW]IO"X,=L8?+\L,/[S9SN_2O9**VOI8=M;G.>*O#.D^,O"M_X;
MURV$]C>QE''1E/4.I[,IP0?45X]\)_@/XD^%/B^35+'QY'?:7=+Y5Y8/8L@G
M49V-GS" ZGH<="1WKZ#I:2D["<4W<*^5_&W[*=]XN\>ZWXF3QK!:+JEV]R(#
M8%S&&[$^8,_E7U113C)QV"45+<^./^&++[_H?K;_ ,%A_P#CE>R_!/X/S_"'
M3M:M9M=BU8ZG-'*&CMC#Y>Q2,?>;/6O8C24W)RW%&*B] [5\^?#?]GF\\ _%
MB7QQ)XJAU".07(^RK9F,CS3D?-O/3Z5]"#I14IE-7*4T4=U"\$T:RQNI5T=<
MJP/!!!ZBOGFU_9=L-)^,5AXR\/Z^+'2;._CODTI[8N4VMN,:R;A\N>F0<#CG
M%?20I#UH4F+E3W%KQ'XV? ^Z^+6I:+=0>)(M(&FQ2QE7M3-YF\J<\,N,;?UK
MVZBCF:>@[71\<_\ #%U]_P!#];?^"P__ !RNM^&G[,-W\/\ XCZ5XND\7P7R
MZ>9";=+$QE]T;)][><?>STKZ:HJN9DJ"05\_?$C]GV\\>_%JV\<1>*HM/CA%
ML/LK69D)\IMWWMXZ_3BOH'O2=Z6Q5KABOFCQ1^S&UU\2W\:>!_%R^%Y#.MY'
M MF9!!/G+,A#C"D\[<8Y(Z'%?3%%+F:$XIF;8K>1V%NNH3137BQJ)GA0HC/C
MDJ"20">V363XK\)>'_''AN?P_P"(M-2]L9N=I^5HV'1T8<JP[$?R-=1104?'
MNO?L:W!OFD\,^-(OLI/RQ:C;$R(/3>APW_?(I]M^QOC1)5NO' &JLR^68K+]
MQ&N?FR"VYB1T.1CT-?7M%/GEW%R1['!?"?P%-\-?AY:^$YM434W@FEE^T)%Y
M0.]RV-N3TSZU>^(WA&3QY\.=9\)17RV#ZC&L8N&C\P1X=6SMR,_=QUKL#0*+
MZW"VECXY;]B[4&//Q MS]=-/_P <I&_8MOF0K_PGUKR,?\@P_P#QROL>BCG9
M'(C,T>Q.EZ%8::9!*;2WC@W@8#;5"YQVZ5X]\;/@7=?%S6=)U"'Q)%I L+:2
M H]J9M^Y@<Y#+CI7NE)4)NY;6ADZ'IS:/X<TW26E$S65K%;F0# ?8@7..V<5
MDZIX7DOM3EO%O GF8^4QYQ@ =<UUC4G:L*M*%;W*BNBX2<7H9.BZ8VE6!MVF
9\TERVX+CK6G3FZ"HZUHTHQ@DC&K)N5S_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
